# Reduced ULK1 links impaired autophagy and mitophagy to Alzheimer's disease pathology.

- **DOI:** [10.1038/s43587-026-01108-z](https://doi.org/10.1038/s43587-026-01108-z)
- **Rating:** Limited (2.7 out of 5)
- **Verdict:** ULK1 emerges as a credible preclinical Alzheimer’s target, but non-independent analyses and confounded human comparisons materially weaken the evidence chain.
- **Framework version:** v5.9
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-10-08
- **Evaluation page:** https://www.nabu.science/paper/10.1038%2Fs43587-026-01108-z

## Key claims

1. In AD mice, ULK1 overexpression stimulates autophagic flux, reduces AD pathology and delays cognitive decline alongside increased phagocytic degradation of amyloid-β, reduced tauopathy and improved mitochondrial quality.
   - Support: Supported
   - Type: Primary finding
   - Basis: two transgenic models support protective effects, but single-age cognition and small mechanistic samples limit the breadth of inference
   - Location: Abstract; Results, Figs. 3–6
2. reduced ULK1 in serum and cerebrospinal fluid during aging in cognitively unimpaired participants from the COGNORM study (n = 75) and in patients with AD from the NorCog Memory Clinic Cohort (n = 316)
   - Support: Tentative
   - Type: Secondary
   - Basis: small paired follow-up and confounded cohort comparisons conflict with null and positive age associations in regression analyses
   - Location: Abstract; Results, Fig. 1a–b, g–h
3. higher autophagy and mitophagy increase cellular NAD+, which in turn deacetylates acetylated-Tau174 via the NAD+-SIRT1 axis, leading to reduced tauopathy
   - Support: Tentative
   - Type: Secondary
   - Basis: correlated pathway readouts and one SIRT1-inhibitor experiment do not directly identify the full NAD+-mediated causal chain
   - Location: Abstract; Results, Fig. 6
4. Using in vitro tau seeding assays and a Caenorhabditis elegans tau model, we validate the efficacy of ULK1 activators in inhibiting tauopathy.
   - Support: Tentative
   - Type: Secondary
   - Basis: pooled fields and mixed activator results support proof of concept but not robust efficacy or mammalian translation
   - Location: Abstract; Results, Fig. 7
5. higher baseline CSF ULK1 was associated with slower progression to AD
   - Support: Supported
   - Type: Secondary
   - Basis: an adjusted longitudinal mixed model supports association, not a protective causal effect
   - Location: Results, Fig. 1l

## Strengths

- **Broad cross-system evidence chain** Human biofluids and brain tissue are connected to two AD mouse models, cultured cells, and C. elegans, providing multiple tests of the ULK1 hypothesis.
  - Dimension: contribution
  - Location: Results, Figs. 1–7
- **Genetic testing across AD pathologies** ULK1 overexpression is evaluated in both 5xFAD amyloid and hTau.P301S tau models, with behavioral and pathological outcomes reported in each.
  - Dimension: methodological rigour
  - Location: Results, Figs. 3–6
- **Adjusted longitudinal progression analysis** The CDR-SB analysis models baseline CSF ULK1 by time while adjusting for demographic, clinical, Aβ, and p-tau variables.
  - Dimension: methodological rigour
  - Location: Results, Fig. 1l; Statistics and Reproducibility

## Limitations

- **Non-independent observations drive inference** Several central cell and imaging analyses use neurons, fields, plaques, or technical repeats as inferential observations despite only three biological replicates or a small number of animals.
  - Dimension: methodological rigour
  - Location: Figs. 2j–k, 3q–s, 4e–f, 6i–l and 7a–e
- **Clinical comparisons retain major confounding** CU controls and AD participants differ in recruitment setting, age, sex, education, APOE status, sampling context, and biomarker laboratory, without a demonstrated adjusted disease-group ULK1 comparison.
  - Dimension: methodological rigour
  - Location: Table 1; Methods, Study Participants; Results, Fig. 1g–h
- **Aging narrative conflicts with regressions** The Discussion reports a null age association in CU participants and a positive ULK1–age association in AD, yet the Abstract and later Discussion assert age-related decline and a causative role.
  - Dimension: positioning
  - Location: Abstract; Discussion, paragraphs 1 and 4; Supplementary Tables 5–6

## Reliability checks

Caveats (4 of 4 checks).

- **Results check:** Clean. The reported numbers and statistics are consistent with the stated results.
- **Reporting and transparency:** Noted. Treatment timing, Golgi sample age, ATP tissue source, serum statistical testing and an Extended Data reference have conflicting descriptions; their effects on the reported results cannot be established.
  - Ethics approval: declared · Preregistration: not stated · Data availability: declared · Code availability: not stated
- **Reference integrity:** Clean. 112 of 112 checkable references verified
  - 113 references in manuscript
  - 1 have no canonical index record — counted, but not index-checkable
  - 3 references confirmed by manual review
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-10-17
